Altimmune Q1 net loss $22.6M; cash $535M; PERFORMA Phase 3 MASH trial initiation in H2 2026

Altimmune, Inc.

Net loss of $22.6M ($0.18 loss per share) vs $19.6M ($0.26) in Q1 2025; R&D $16.2M, G&A $8.1M.
Cash, equivalents and short-term investments $332M at Mar 31, 2026; $535M at Apr 30, 2026 after $225M public offering.
Initiation of PERFORMA Phase 3 MASH trial planned for H2 2026; topline RECLAIM Phase 2 AUD data expected Q3 2026; RESTORE Phase 2 ALD enrollment completion Q3 2026.
Pemvidutide received Breakthrough Therapy Designation for MASH; EASL presentations on May 28, 2026 including 48-week IMPACT data.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Altimmune, Inc. reported the first quarter ended March 31, 2026 results: net income $22.6 million, or $0.18 net loss per share.

Period: the first quarter ended March 31, 2026
Net income: $22.6 million, or $0.18 net loss per share
Result: reported results

Exact text from the filing

Altimmune, Inc. (the “Company”) issued a press release announcing the Company’s financial results for its first quarter ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

Altimmune, Inc. filing history →

Source: SEC EDGAR

accession 0001326190-26-000037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.